1 Executive Summary
2 Preface
2.1 Abstract
2.2 Stake Holders
2.3 Research Scope
2.4 Research Methodology
2.4.1 Data Mining
2.4.2 Data Analysis
2.4.3 Data Validation
2.4.4 Research Approach
2.5 Research Sources
2.5.1 Primary Research Sources
2.5.2 Secondary Research Sources
2.5.3 Assumptions
3 Market Trend Analysis
3.1 Introduction
3.2 Drivers
3.3 Restraints
3.4 Opportunities
3.5 Threats
3.6 Emerging Markets
3.7 Impact of Covid-19
4 Porters Five Force Analysis
4.1 Bargaining power of suppliers
4.2 Bargaining power of buyers
4.3 Threat of substitutes
4.4 Threat of new entrants
4.5 Competitive rivalry
5 Global Cystic Fibrosis Market, By Drug Class
5.1 Introduction
5.2 Pancreatic Enzyme Supplements
5.3 Mucolytic
5.4 Bronchodilators
5.5 Antibiotics
5.6 Cystic Fibrosis Transmembrane Conductance Regulator Modulators
5.7 Other Drug Classes
6 Global Cystic Fibrosis Market, By Treatment Method
6.1 Introduction
6.2 Medication
6.3 Devices
7 Global Cystic Fibrosis Market, By Route of Administration
7.1 Introduction
7.2 Oral
7.3 Inhaled
8 Global Cystic Fibrosis Market, By Distribution Channel
8.1 Introduction
8.2 Hospital
8.3 Drug Stores
8.4 Retail Pharmacies
8.5 Other Distribution Channels
9 Global Cystic Fibrosis Market, By Geography
9.1 Introduction
9.2 North America
9.2.1 US
9.2.2 Canada
9.2.3 Mexico
9.3 Europe
9.3.1 Germany
9.3.2 UK
9.3.3 Italy
9.3.4 France
9.3.5 Spain
9.3.6 Rest of Europe
9.4 Asia Pacific
9.4.1 Japan
9.4.2 China
9.4.3 India
9.4.4 Australia
9.4.5 New Zealand
9.4.6 South Korea
9.4.7 Rest of Asia Pacific
9.5 South America
9.5.1 Argentina
9.5.2 Brazil
9.5.3 Chile
9.5.4 Rest of South America
9.6 Middle East & Africa
9.6.1 Saudi Arabia
9.6.2 UAE
9.6.3 Qatar
9.6.4 South Africa
9.6.5 Rest of Middle East & Africa
10 Key Developments
10.1 Agreements, Partnerships, Collaborations and Joint Ventures
10.2 Acquisitions & Mergers
10.3 New Product Launch
10.4 Expansions
10.5 Other Key Strategies
11 Company Profiling
11.1 Pharmaxis Ltd
11.2 Gilead Sciences, Inc.
11.3 Teva Pharmaceuticals
11.4 Genentech Inc
11.5 AbbVie Inc.
11.6 Mylan N.V
11.7 Viatris Inc.
11.8 Novartis AG
11.9 Allergan PLC
11.10 Pfizer Inc
11.11 Nestle Health Science
11.12 Hoffmann-La Roche AG
11.13 BayerAG
11.14 Vertex Pharmaceuticals Incorporated
11.15 AstraZeneca
11.16 Chiesi Farmaceutici SpA
11.17 Horizon Therapeutic Plc.
List of Tables
Table 1 Global Cystic Fibrosis Market Outlook, By Region (2021-2030) ($MN)
Table 2 Global Cystic Fibrosis Market Outlook, By Drug Class (2021-2030) ($MN)
Table 3 Global Cystic Fibrosis Market Outlook, By Pancreatic Enzyme Supplements (2021-2030) ($MN)
Table 4 Global Cystic Fibrosis Market Outlook, By Mucolytic (2021-2030) ($MN)
Table 5 Global Cystic Fibrosis Market Outlook, By Bronchodilators (2021-2030) ($MN)
Table 6 Global Cystic Fibrosis Market Outlook, By Antibiotics (2021-2030) ($MN)
Table 7 Global Cystic Fibrosis Market Outlook, By Cystic Fibrosis Transmembrane Conductance Regulator Modulators (2021-2030) ($MN)
Table 8 Global Cystic Fibrosis Market Outlook, By Other Drug Classes (2021-2030) ($MN)
Table 9 Global Cystic Fibrosis Market Outlook, By Treatment Method (2021-2030) ($MN)
Table 10 Global Cystic Fibrosis Market Outlook, By Medication (2021-2030) ($MN)
Table 11 Global Cystic Fibrosis Market Outlook, By Devices (2021-2030) ($MN)
Table 12 Global Cystic Fibrosis Market Outlook, By Route of Administration (2021-2030) ($MN)
Table 13 Global Cystic Fibrosis Market Outlook, By Oral (2021-2030) ($MN)
Table 14 Global Cystic Fibrosis Market Outlook, By Inhaled (2021-2030) ($MN)
Table 15 Global Cystic Fibrosis Market Outlook, By Distribution Channel (2021-2030) ($MN)
Table 16 Global Cystic Fibrosis Market Outlook, By Hospital (2021-2030) ($MN)
Table 17 Global Cystic Fibrosis Market Outlook, By Drug Stores (2021-2030) ($MN)
Table 18 Global Cystic Fibrosis Market Outlook, By Retail Pharmacies (2021-2030) ($MN)
Table 19 Global Cystic Fibrosis Market Outlook, By Other Distribution Channels (2021-2030) ($MN)
Table 20 North America Cystic Fibrosis Market Outlook, By Country (2021-2030) ($MN)
Table 21 North America Cystic Fibrosis Market Outlook, By Drug Class (2021-2030) ($MN)
Table 22 North America Cystic Fibrosis Market Outlook, By Pancreatic Enzyme Supplements (2021-2030) ($MN)
Table 23 North America Cystic Fibrosis Market Outlook, By Mucolytic (2021-2030) ($MN)
Table 24 North America Cystic Fibrosis Market Outlook, By Bronchodilators (2021-2030) ($MN)
Table 25 North America Cystic Fibrosis Market Outlook, By Antibiotics (2021-2030) ($MN)
Table 26 North America Cystic Fibrosis Market Outlook, By Cystic Fibrosis Transmembrane Conductance Regulator Modulators (2021-2030) ($MN)
Table 27 North America Cystic Fibrosis Market Outlook, By Other Drug Classes (2021-2030) ($MN)
Table 28 North America Cystic Fibrosis Market Outlook, By Treatment Method (2021-2030) ($MN)
Table 29 North America Cystic Fibrosis Market Outlook, By Medication (2021-2030) ($MN)
Table 30 North America Cystic Fibrosis Market Outlook, By Devices (2021-2030) ($MN)
Table 31 North America Cystic Fibrosis Market Outlook, By Route of Administration (2021-2030) ($MN)
Table 32 North America Cystic Fibrosis Market Outlook, By Oral (2021-2030) ($MN)
Table 33 North America Cystic Fibrosis Market Outlook, By Inhaled (2021-2030) ($MN)
Table 34 North America Cystic Fibrosis Market Outlook, By Distribution Channel (2021-2030) ($MN)
Table 35 North America Cystic Fibrosis Market Outlook, By Hospital (2021-2030) ($MN)
Table 36 North America Cystic Fibrosis Market Outlook, By Drug Stores (2021-2030) ($MN)
Table 37 North America Cystic Fibrosis Market Outlook, By Retail Pharmacies (2021-2030) ($MN)
Table 38 North America Cystic Fibrosis Market Outlook, By Other Distribution Channels (2021-2030) ($MN)
Table 39 Europe Cystic Fibrosis Market Outlook, By Country (2021-2030) ($MN)
Table 40 Europe Cystic Fibrosis Market Outlook, By Drug Class (2021-2030) ($MN)
Table 41 Europe Cystic Fibrosis Market Outlook, By Pancreatic Enzyme Supplements (2021-2030) ($MN)
Table 42 Europe Cystic Fibrosis Market Outlook, By Mucolytic (2021-2030) ($MN)
Table 43 Europe Cystic Fibrosis Market Outlook, By Bronchodilators (2021-2030) ($MN)
Table 44 Europe Cystic Fibrosis Market Outlook, By Antibiotics (2021-2030) ($MN)
Table 45 Europe Cystic Fibrosis Market Outlook, By Cystic Fibrosis Transmembrane Conductance Regulator Modulators (2021-2030) ($MN)
Table 46 Europe Cystic Fibrosis Market Outlook, By Other Drug Classes (2021-2030) ($MN)
Table 47 Europe Cystic Fibrosis Market Outlook, By Treatment Method (2021-2030) ($MN)
Table 48 Europe Cystic Fibrosis Market Outlook, By Medication (2021-2030) ($MN)
Table 49 Europe Cystic Fibrosis Market Outlook, By Devices (2021-2030) ($MN)
Table 50 Europe Cystic Fibrosis Market Outlook, By Route of Administration (2021-2030) ($MN)
Table 51 Europe Cystic Fibrosis Market Outlook, By Oral (2021-2030) ($MN)
Table 52 Europe Cystic Fibrosis Market Outlook, By Inhaled (2021-2030) ($MN)
Table 53 Europe Cystic Fibrosis Market Outlook, By Distribution Channel (2021-2030) ($MN)
Table 54 Europe Cystic Fibrosis Market Outlook, By Hospital (2021-2030) ($MN)
Table 55 Europe Cystic Fibrosis Market Outlook, By Drug Stores (2021-2030) ($MN)
Table 56 Europe Cystic Fibrosis Market Outlook, By Retail Pharmacies (2021-2030) ($MN)
Table 57 Europe Cystic Fibrosis Market Outlook, By Other Distribution Channels (2021-2030) ($MN)
Table 58 Asia Pacific Cystic Fibrosis Market Outlook, By Country (2021-2030) ($MN)
Table 59 Asia Pacific Cystic Fibrosis Market Outlook, By Drug Class (2021-2030) ($MN)
Table 60 Asia Pacific Cystic Fibrosis Market Outlook, By Pancreatic Enzyme Supplements (2021-2030) ($MN)
Table 61 Asia Pacific Cystic Fibrosis Market Outlook, By Mucolytic (2021-2030) ($MN)
Table 62 Asia Pacific Cystic Fibrosis Market Outlook, By Bronchodilators (2021-2030) ($MN)
Table 63 Asia Pacific Cystic Fibrosis Market Outlook, By Antibiotics (2021-2030) ($MN)
Table 64 Asia Pacific Cystic Fibrosis Market Outlook, By Cystic Fibrosis Transmembrane Conductance Regulator Modulators (2021-2030) ($MN)
Table 65 Asia Pacific Cystic Fibrosis Market Outlook, By Other Drug Classes (2021-2030) ($MN)
Table 66 Asia Pacific Cystic Fibrosis Market Outlook, By Treatment Method (2021-2030) ($MN)
Table 67 Asia Pacific Cystic Fibrosis Market Outlook, By Medication (2021-2030) ($MN)
Table 68 Asia Pacific Cystic Fibrosis Market Outlook, By Devices (2021-2030) ($MN)
Table 69 Asia Pacific Cystic Fibrosis Market Outlook, By Route of Administration (2021-2030) ($MN)
Table 70 Asia Pacific Cystic Fibrosis Market Outlook, By Oral (2021-2030) ($MN)
Table 71 Asia Pacific Cystic Fibrosis Market Outlook, By Inhaled (2021-2030) ($MN)
Table 72 Asia Pacific Cystic Fibrosis Market Outlook, By Distribution Channel (2021-2030) ($MN)
Table 73 Asia Pacific Cystic Fibrosis Market Outlook, By Hospital (2021-2030) ($MN)
Table 74 Asia Pacific Cystic Fibrosis Market Outlook, By Drug Stores (2021-2030) ($MN)
Table 75 Asia Pacific Cystic Fibrosis Market Outlook, By Retail Pharmacies (2021-2030) ($MN)
Table 76 Asia Pacific Cystic Fibrosis Market Outlook, By Other Distribution Channels (2021-2030) ($MN)
Table 77 South America Cystic Fibrosis Market Outlook, By Country (2021-2030) ($MN)
Table 78 South America Cystic Fibrosis Market Outlook, By Drug Class (2021-2030) ($MN)
Table 79 South America Cystic Fibrosis Market Outlook, By Pancreatic Enzyme Supplements (2021-2030) ($MN)
Table 80 South America Cystic Fibrosis Market Outlook, By Mucolytic (2021-2030) ($MN)
Table 81 South America Cystic Fibrosis Market Outlook, By Bronchodilators (2021-2030) ($MN)
Table 82 South America Cystic Fibrosis Market Outlook, By Antibiotics (2021-2030) ($MN)
Table 83 South America Cystic Fibrosis Market Outlook, By Cystic Fibrosis Transmembrane Conductance Regulator Modulators (2021-2030) ($MN)
Table 84 South America Cystic Fibrosis Market Outlook, By Other Drug Classes (2021-2030) ($MN)
Table 85 South America Cystic Fibrosis Market Outlook, By Treatment Method (2021-2030) ($MN)
Table 86 South America Cystic Fibrosis Market Outlook, By Medication (2021-2030) ($MN)
Table 87 South America Cystic Fibrosis Market Outlook, By Devices (2021-2030) ($MN)
Table 88 South America Cystic Fibrosis Market Outlook, By Route of Administration (2021-2030) ($MN)
Table 89 South America Cystic Fibrosis Market Outlook, By Oral (2021-2030) ($MN)
Table 90 South America Cystic Fibrosis Market Outlook, By Inhaled (2021-2030) ($MN)
Table 91 South America Cystic Fibrosis Market Outlook, By Distribution Channel (2021-2030) ($MN)
Table 92 South America Cystic Fibrosis Market Outlook, By Hospital (2021-2030) ($MN)
Table 93 South America Cystic Fibrosis Market Outlook, By Drug Stores (2021-2030) ($MN)
Table 94 South America Cystic Fibrosis Market Outlook, By Retail Pharmacies (2021-2030) ($MN)
Table 95 South America Cystic Fibrosis Market Outlook, By Other Distribution Channels (2021-2030) ($MN)
Table 96 Middle East & Africa Cystic Fibrosis Market Outlook, By Country (2021-2030) ($MN)
Table 97 Middle East & Africa Cystic Fibrosis Market Outlook, By Drug Class (2021-2030) ($MN)
Table 98 Middle East & Africa Cystic Fibrosis Market Outlook, By Pancreatic Enzyme Supplements (2021-2030) ($MN)
Table 99 Middle East & Africa Cystic Fibrosis Market Outlook, By Mucolytic (2021-2030) ($MN)
Table 100 Middle East & Africa Cystic Fibrosis Market Outlook, By Bronchodilators (2021-2030) ($MN)
Table 101 Middle East & Africa Cystic Fibrosis Market Outlook, By Antibiotics (2021-2030) ($MN)
Table 102 Middle East & Africa Cystic Fibrosis Market Outlook, By Cystic Fibrosis Transmembrane Conductance Regulator Modulators (2021-2030) ($MN)
Table 103 Middle East & Africa Cystic Fibrosis Market Outlook, By Other Drug Classes (2021-2030) ($MN)
Table 104 Middle East & Africa Cystic Fibrosis Market Outlook, By Treatment Method (2021-2030) ($MN)
Table 105 Middle East & Africa Cystic Fibrosis Market Outlook, By Medication (2021-2030) ($MN)
Table 106 Middle East & Africa Cystic Fibrosis Market Outlook, By Devices (2021-2030) ($MN)
Table 107 Middle East & Africa Cystic Fibrosis Market Outlook, By Route of Administration (2021-2030) ($MN)
Table 108 Middle East & Africa Cystic Fibrosis Market Outlook, By Oral (2021-2030) ($MN)
Table 109 Middle East & Africa Cystic Fibrosis Market Outlook, By Inhaled (2021-2030) ($MN)
Table 110 Middle East & Africa Cystic Fibrosis Market Outlook, By Distribution Channel (2021-2030) ($MN)
Table 111 Middle East & Africa Cystic Fibrosis Market Outlook, By Hospital (2021-2030) ($MN)
Table 112 Middle East & Africa Cystic Fibrosis Market Outlook, By Drug Stores (2021-2030) ($MN)
Table 113 Middle East & Africa Cystic Fibrosis Market Outlook, By Retail Pharmacies (2021-2030) ($MN)
Table 114 Middle East & Africa Cystic Fibrosis Market Outlook, By Other Distribution Channels (2021-2030) ($MN)
| ※参考情報 嚢胞性線維症（Cystic Fibrosis）は、遺伝性の重篤な疾患で、主に呼吸器系や消化器系に影響を及ぼします。この病気は、体内の粘液が異常に粘り気を持ち、特定の臓器に蓄積することによって引き起こされます。原因は、CFTM（Cystic Fibrosis Transmembrane Conductance Regulator）遺伝子の変異です。この遺伝子は、細胞膜を通じて塩素イオンの輸送を制御する役割を果たしています。CFTM遺伝子に変異がある場合、塩素イオンの輸送が正常に行われず、その結果として粘液の構造と性質に変化が生じます。 嚢胞性線維症には、多くの異なる変異があり、そのため症状や病状の進行には個人差があります。主な症状には、呼吸器感染、慢性的な咳、呼吸困難、消化不良、栄養吸収障害などが含まれます。呼吸器系においては、粘性の高い痰が気道を塞ぎ、細菌感染を引き起こしやすくなります。また、消化器系では、膵臓の機能が低下し、消化酵素の分泌が不足してしまうことがあり、そのため食事からの栄養吸収が不十分になります。 嚢胞性線維症は、全世界で約1万人に1人の割合で発症すると言われていますが、この割合は人種や地域によって異なります。特に白人の新生児に多く見られる遺伝子疾患です。この病気は完全に治癒する方法は現在のところ存在せず、治療は主に症状を軽減し、生活の質を向上させることに重点が置かれています。 治療法には、呼吸理学療法、薬物療法、栄養管理が含まれます。呼吸理学療法は、粘液の排出を促進するために行われ、肺機能の維持に役立ちます。薬物療法には、抗生物質や粘液溶解薬などがあり、感染症の予防や呼吸機能の改善を目指します。また、栄養管理においては、高カロリー・高たんぱく質の食事が推奨され、ビタミンやミネラルの補充も行われます。 最近では、遺伝子治療や新しい薬に関する研究が進んでおり、一部の患者に対しては、CFTM蛋白質の機能を改善する医薬品が利用可能になっています。これにより、症状の改善や病状の安定化が期待されており、治療選択肢が広がる可能性があります。このような新たな技術や治療法により、今後は患者の生存期間や生活の質が向上することが期待されています。 また、嚢胞性線維症は、遺伝性疾患であるため、家族計画においても重要な考慮事項となります。遺伝子検査を通じて、CFTM遺伝子の変異の有無を調べることができ、リスクを理解することが可能です。特に、患家族に嚢胞性線維症の方がいる場合、遺伝カウンセリングを受けることが推奨されます。 現在、全世界で嚢胞性線維症に対する意識が高まり、研究が進むことで、より良い治療法が開発されることが期待されています。特に、地域社会におけるサポートや、患者の生活支援プログラムが重要な役割を果たしており、生活の質を向上させる取り組みが進められています。 以上のように、嚢胞性線維症は多岐にわたる症状と治療方針を持ち、今後の研究や技術の進展により、患者にとってより良い未来が開かれることが期待されます。適切な治療とサポートを受けることによって、多くの患者が豊かな人生を送ることができるようになることが望まれています。 |
